Reveal Pharmaceuticals logo
Remote hiring company

Remote jobs at Reveal Pharmaceuticals

The gadolinium-free MRI contrast agent - The future of medical insight

BiotechnologyScienceHealthcareMedTech
Company overview

About Reveal Pharmaceuticals

Reveal is a clinical-stage biotechnology company developing a next-generation MRI contrast agent currently in Phase 2 clinical trials with FDA Fast Track designation. Our mission is to transform contrast-enhanced MRI and address three major challenges: patient safety, environmental impact, and healthcare supply-chain resilience. More than 60 million MRI scans with contrast are performed each year. Current contrast agents rely on the heavy metal gadolinium, which accumulates in patients, contributes to rising levels of gadolinium in surface waters, and depends on a vulnerable rare-earth supply chain. Reveal’s patented gadolinium-free contrast agents use manganese, an element that is abundant in nature and essential for human biology. Our work has been awarded over $15 million in NIH SBIR grant funding, reflecting strong validation of our technology and its potential impact. Our investors include patients, physicians, and industry experts who share our commitment to advancing safer and more sustainable medical imaging.

Purpose

Mission and direction

Reveal Pharmaceuticals develops a next-generation, gadolinium-free MRI contrast agent based on manganese to improve patient safety, reduce environmental impact, and strengthen healthcare supply-chain resilience. The company is advancing a first-in-class small molecule parenteral drug through clinical development, with the goal of translating exceptional science into a safer, more sustainable imaging medicine for millions of patients worldwide.

How they work

Company values

  • Patient safety
  • Scientific rigor
  • Innovation
  • Sustainability
  • Collaboration
  • Accountability
  • Integrity